These data provide evidence for the role of PIM kinases in chemoresistance in hepatoblastoma and propose PIM inhibition as a strategy to potentially overcome cisplatin resistance by targeting the SCLCC phenotype. Here, PIM1 is linked to hepatoblastoma.